The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: The experience of the BIG 02-98 trial

Evandro De Azambuja, Worta McCaskill-Stevens, Prudence Francis, Emmanuel Quinaux, John P A Crown, Malou Vicente, Rosa Giuliani, Bo Nordenskjöld, Jorge Gutiérez, Michael Andersson, Mireia Margeli Vila, Raimund Jakesz, Jan Demol, Joanna Dewar, Armando Santoro, Ana Lluch, Steven Olsen, Richard D. Gelber, Angelo Di Leo, Martine Piccart-Gebhart

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Obesity has been shown to be an indicator of poor prognosis for patients with primary breast cancer (BC) regardless of the use of adjuvant systemic therapy. Patients and methods: This is a retrospective analysis of 2,887 node-positive BC patients enrolled in the BIG 02-98 adjuvant study, a randomised phase III trial whose primary objective was to evaluate disease-free survival (DFS) by adding docetaxel to doxorubicin-based chemotherapy. In the current analysis, the effect of body mass index (BMI) on DFS and overall survival (OS) was assessed. BMI was obtained before the first cycle of chemotherapy. Obesity was defined as a BMI ≥ 30 kg/m2. Results: In total 547 (19%) patients were obese at baseline, while 2,340 (81%) patients were non-obese. Estimated 5-year OS was 87.5% for non-obese and 82.9% for obese patients (HR 1.34; P = 0.013). Estimated 5-years DFS was 75.9% for non-obese and 70.0% for obese patients (HR 1.20; P = 0.041). In a multivariate model, obesity remained an independent prognostic factor for OS and DFS. Conclusions: In this study, obesity was associated with poorer outcome in node-positive BC patients. Given the increasing prevalence of obesity worldwide, more research on improving the treatment of obese BC patients is needed.

Original languageEnglish
Pages (from-to)145-153
Number of pages9
JournalBreast Cancer Research and Treatment
Volume119
Issue number1
DOIs
Publication statusPublished - Jan 2010

Keywords

  • Adjuvant chemotherapy
  • BMI
  • Breast cancer
  • Docetaxel
  • Node-positive
  • Obesity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: The experience of the BIG 02-98 trial'. Together they form a unique fingerprint.

Cite this